BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 32771615)

  • 21. Impact of Duration of Neoadjuvant Radiation on Rectal Cancer Survival: A Real World Multi-center Retrospective Cohort Study.
    Abdel-Rahman O; Kumar A; Kennecke HF; Speers CH; Cheung WY
    Clin Colorectal Cancer; 2018 Mar; 17(1):e21-e28. PubMed ID: 28709877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
    Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
    Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
    Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
    ; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
    Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.
    Sandler KA; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Song DY; Klein EA; Stephenson AJ; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco SC; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR; Kishan AU
    Eur Urol; 2020 Jan; 77(1):3-10. PubMed ID: 30992160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers.
    Johnson SB; Park HS; Gross CP; Yu JB
    JAMA Oncol; 2018 Oct; 4(10):1375-1381. PubMed ID: 30027204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.
    Tendulkar RD; Hunter GK; Reddy CA; Stephans KL; Ciezki JP; Abdel-Wahab M; Stephenson AJ; Klein EA; Mahadevan A; Kupelian PA
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):94-9. PubMed ID: 23920389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
    Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
    Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comorbidity as a predictor of overall survival in prostate cancer patients treated with external beam radiotherapy combined with HDR brachytherapy boosts.
    Hjälm-Eriksson M; Ullén A; Johansson H; Levitt S; Nilsson S; Kälkner KM
    Acta Oncol; 2017 Jan; 56(1):21-26. PubMed ID: 27882806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The outcome and the frequency of pathological complete response after neoadjuvant radiotherapy in curative resections for advanced rectal cancer: a population-based study.
    Wasmuth HH; Rekstad LC; Tranø G
    Colorectal Dis; 2016 Jan; 18(1):67-72. PubMed ID: 26201935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.
    Takei A; Sakamoto S; Wakai K; Tamura T; Imamura Y; Xu M; Maimaiti M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
    Int J Urol; 2018 Apr; 25(4):352-358. PubMed ID: 29323427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire.
    Chahal R; Sundaram SK; Iddenden R; Forman DF; Weston PM; Harrison SC
    Eur Urol; 2003 Mar; 43(3):246-57. PubMed ID: 12600427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cervical Cancer in Ethiopia: The Effect of Adherence to Radiotherapy on Survival.
    Moelle U; Mathewos A; Aynalem A; Wondemagegnehu T; Yonas B; Begoihn M; Addissie A; Unverzagt S; Jemal A; Thomssen C; Vordermark D; Kantelhardt EJ
    Oncologist; 2018 Sep; 23(9):1024-1032. PubMed ID: 29567823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lower risk of major cardiovascular events associated with adherence to colesevelam HCI.
    Ye X; Qian C; Liu J; St Peter WL
    Pharmacotherapy; 2013 Oct; 33(10):1062-70. PubMed ID: 23798059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of age on variation in patterns of care in patients with rectal cancer in Catalonia (Spain).
    Vernet R; Borras JM; Aliste L; Antonio M; Guarga A; Manchon-Walsh P
    Clin Transl Oncol; 2018 Dec; 20(12):1538-1547. PubMed ID: 29766457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic overview of radiation therapy effects in prostate cancer.
    Nilsson S; Norlén BJ; Widmark A
    Acta Oncol; 2004; 43(4):316-81. PubMed ID: 15303499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity.
    Jolnerovski M; Salleron J; Beckendorf V; Peiffert D; Baumann AS; Bernier V; Huger S; Marchesi V; Chira C
    Radiat Oncol; 2017 Jun; 12(1):99. PubMed ID: 28622770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer.
    Dong Y; Zaorsky NG; Li T; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MA; Horwitz EM
    J Med Imaging Radiat Oncol; 2018 Feb; 62(1):116-121. PubMed ID: 29030906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation.
    Hsu IC; Pickett B; Shinohara K; Krieg R; Roach M; Phillips T
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):851-8. PubMed ID: 10705005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating Adherence Based on Prescription or Dispensation Information: Impact on Thresholds and Outcomes. A Real-World Study With Atrial Fibrillation Patients Treated With Oral Anticoagulants in Spain.
    Hurtado-Navarro I; García-Sempere A; Rodríguez-Bernal C; Santa-Ana-Tellez Y; Peiró S; Sanfélix-Gimeno G
    Front Pharmacol; 2018; 9():1353. PubMed ID: 30559661
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.